在治疗儿科低级结质瘤的进展
Inci Yaman Bajin1, Eric Bouffet2
1Division of Paediatric Haematology-Oncology, Department of Paediatrics, Hospital for Sick Children, Toronto,, Canada. inci.yaman@sickkids.ca.
Current neurology and neuroscience reports
|August 14, 2024
概括
儿科低度质瘤 (pLGGs) 的治疗方法正在发展. 针对性疗法在改善治疗结果和减少这些脑瘤的长期副作用方面表现有前途.
科学领域:
- 儿科瘤学 儿科瘤学
- 神经瘤学神经瘤学
- 分子生物学分子生物学
背景情况:
- 儿科低度结质瘤 (pLGGs) 呈现出显著的长期发病率,尽管生存率高.
- 了解PLGGs复杂的生物学和分子特征对于推进治疗至关重要.
研究的目的:
- 审查目前关于PLGG生物学和分子特征的知识.
- 为 pLGGs 提供既定和新的治疗策略的概述.
主要方法:
- 关于儿科低度质瘤研究的文献综述.
- 对分子基础和治疗结果的分析.
主要成果:
- 关键的遗传异常包括BRAF融合/突变和RAS/MAPK/mTOR通路的参与.
- 向疗法 (MEK,BRAF,泛RAF抑制剂) 在临床试验中显示出有效性和可控毒性.
- 个性化治疗方法正在改善结果,并可能减少长期的毒性.
结论:
- 了解PLGG分子生物学方面的进步正在推动针对性治疗的发展.
- 向性药物为传统治疗提供了一个有前途的替代方案,有可能减少长期疾病.
- 未来的研究应该专注于优化治疗序列,长期影响评估和全球获得新型疗法.
相关概念视频
02:57Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...
02:56Treatment Resistent Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...